KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Current Deferred Revenue (2016 - 2025)

Medpace Holdings (MEDP) has disclosed Current Deferred Revenue for 11 consecutive years, with $808.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Current Deferred Revenue changed N/A year-over-year to $808.8 million, compared with a TTM value of $808.8 million through Jun 2025, changed N/A, and an annual FY2023 reading of $559.9 million, up 20.99% over the prior year.
  • Current Deferred Revenue was $808.8 million for Q2 2025 at Medpace Holdings, up from $670.9 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $808.8 million in Q2 2025 and bottomed at $277.8 million in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $494.1 million, with a median of $462.7 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue soared 46.55% in 2021, then grew 20.99% in 2023.
  • Year by year, Current Deferred Revenue stood at $344.6 million in 2021, then soared by 34.26% to $462.7 million in 2022, then increased by 20.99% to $559.9 million in 2023, then increased by 19.84% to $670.9 million in 2024, then grew by 20.54% to $808.8 million in 2025.
  • Business Quant data shows Current Deferred Revenue for MEDP at $808.8 million in Q2 2025, $670.9 million in Q3 2024, and $616.7 million in Q1 2024.